Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics

Carey, D. G.; Cowin, G.; Galloway, Graham J.; Doddrell, DavidM.; Richards, JacquelineC.; Jones, NigelP.; Biswas, Nandita

doi:10.1016/s0168-8227(00)81676-9

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study that used the euglycaemic hyperinsulinaemic clamp technique to measure insulin sensitivity supports these findings [34]. This study showed that rosiglitazone monotherapy (8 mg/day) significantly decreased insulin resistance by 78% from baseline ( P = 0.0002) after 16 weeks [34], indicating even greater improvements in insulin sensitivity.…”

Section: Prospects For Preventing the Progression Of Type 2 Diabetessupporting

confidence: 52%

“…For example, studies of rosiglitazone monotherapy (8 mg/day), rosiglitazone (4 mg/day) plus a sulphonylurea, and rosiglitazone (8 mg/day) in combination with metformin have shown decreases in insulin resistance of 33%, 32% and 21%, respectively [26,28,29]. A recent study that used the euglycaemic hyperinsulinaemic clamp technique to measure insulin sensitivity supports these findings [34]. This study showed that rosiglitazone monotherapy (8 mg/day) significantly decreased insulin resistance by 78% from baseline ( P = 0.0002) after 16 weeks [34], indicating even greater improvements in insulin sensitivity.…”

Section: Prospects For Preventing the Progression Of Type 2 Diabetesmentioning

confidence: 99%

See 1 more Smart Citation

Insulin resistance and β‐cell function – a clinical perspective

Matthews

2001

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Section: Prospects For Preventing the Progression Of Type 2 Diabetessupporting

confidence: 52%

Section: Prospects For Preventing the Progression Of Type 2 Diabetesmentioning

confidence: 99%

Insulin resistance and β‐cell function – a clinical perspective

Matthews

2001

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

“…For example, insulin‐stimulated glucose disposal improved by 40–50% following troglitazone therapy in subjects with type 2 diabetes [59,70], while a similar increase was demonstrated in individuals treated with pioglitazone [71]. Recent data indicate that the same is true for rosiglitazone [72]. It is proposed that the thiazolidinediones reduce insulin resistance by enhancing insulin‐stimulated glucose transport, leading to increased rates of muscle glycogen synthesis and glucose oxidation [73].…”

Section: Role Of Ffa In the Development Of Insulin Resistancementioning

confidence: 99%

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction

Boden

Shulman

2002

Eur J Clin Investigation

1,142

812

View full text Add to dashboard Cite

Plasma free fatty acids (FFA) play important physiological roles in skeletal muscle, heart, liver and pancreas. However, chronically elevated plasma FFA appear to have pathophysiological consequences. Elevated FFA concentrations are linked with the onset of peripheral and hepatic insulin resistance and, while the precise action in the liver remains unclear, a model to explain the role of raised FFA in the development of skeletal muscle insulin resistance has recently been put forward. Over 30 years ago, Randle proposed that FFA compete with glucose as the major energy substrate in cardiac muscle, leading to decreased glucose oxidation when FFA are elevated. Recent data indicate that high plasma FFA also have a significant role in contributing to insulin resistance. Elevated FFA and intracellular lipid appear to inhibit insulin signalling, leading to a reduction in insulin-stimulated muscle glucose transport that may be mediated by a decrease in GLUT-4 translocation. The resulting suppression of muscle glucose transport leads to reduced muscle glycogen synthesis and glycolysis. In the liver, elevated FFA may contribute to hyperglycaemia by antagonizing the effects of insulin on endogenous glucose production. FFA also affect insulin secretion, although the nature of this relationship remains a subject for debate. Finally, evidence is discussed that FFA represent a crucial link between insulin resistance and beta-cell dysfunction and, as such, a reduction in elevated plasma FFA should be an important therapeutic target in obesity and type 2 diabetes.

show abstract

“…The estimates of insulin resistance with HOMA analysis have been confirmed by more established techniques. A recent study to examine the effect of rosiglitazone on insulin sensitivity employing a more direct method – the euglycaemic hyperinsulinaemic clamp technique – showed that rosiglitazone monotherapy (8 mg/day) significantly decreases insulin resistance by 78% after 16 weeks ( P = 0.0002) [35].…”

Section: The Metabolic Effects Of Rosiglitazonementioning

confidence: 99%

PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone

Zinman

2001

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics

Cited by 7 publications

References 0 publications

Insulin resistance and β‐cell function – a clinical perspective

Insulin resistance and β‐cell function – a clinical perspective

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction

PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone

Contact Info

Product

Resources

About